Immunological effects and safe administration of alemtuzumab (MabCampathࡊ) in advanced B-CLL

Medical Oncology

Volumn 19, Issue , 2002, Pages S49-S55

  Kennedy, Ben ^a   Hillmen, Peter ^b  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b PINDERFIELDS GENERAL HOSPITAL   (United Kingdom)

Author keywords

Alemtuzumab; B cell; Campath 1H; Chronic; Leukemia; Monoclonal antibody

Indexed keywords

ALEMTUZUMAB; CANCER ANTIBODY; MONOCLONAL ANTIBODY; ALKYLATING AGENT; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DAPSONE; FAMCICLOVIR; FLUCONAZOLE; FLUDARABINE; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; PENTAMIDINE; PURINE DERIVATIVE; SULFONAMIDE;

B CELL LEUKEMIA; COMMUNICABLE DISEASE; HUMAN; IMMUNOLOGY; MULTIPLE SCLEROSIS; REVIEW; RHEUMATOID ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOPENIA; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HIGH RISK PATIENT; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNOTOXICITY; INFECTION PREVENTION; INFECTION SENSITIVITY; META ANALYSIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ARTHRITIS, RHEUMATOID; COMMUNICABLE DISEASES; HUMANS; LEUKEMIA, B-CELL, CHRONIC; MULTIPLE SCLEROSIS; HUMAN;

EID: 0036275222     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:19:2S:S49     Document Type: Article

References (50)

1. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro
2. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis
3. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
4. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H
5. Subcutaneous administration of CAMPATH-1H: Clinical and biological outcomes
6. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody. CAMPATH-1H
7. Emergence of oligoclonal T cell populations following therapeutic T cell depletion in rheumatoid arthritis
8. Prophylaxis against opportunistic infection in patients with human immunodeficiency virus infection
9. CAMPATH-1H in rheumatoid arthritis - An intravenous dose-ranging study
10. Campath-1H is an effective salvage therapy for fludarabine-failing CLL patients; results of a phase II trial
11. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study
12. Campath-1H in CLL: Immune reconstitution and viral infection during and after therapy
13. Campath-1H monoclonal antibody therapy
14. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)
15. Monoclonal antibody therapy in lymphoid malignancies
16. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study
17. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy
18. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)
19. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: High-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia
20. Chronic lymphocytic leukemia
21. A phase II multicenter study of Campath-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma
22. Analysis of response to Campath-1H in patients with B-CLL progressing after fludarabine therapy
23. Multicenter study of Campath-1H in patients with chronic lymphocytic leukemia (B-CLL) refractory to fludarabine
24. Infections in chronic lymphocytic leukemia: Risk factors, and impact on survival, and treatment
25. Chronic indolent orofacial herpes simplex virus infection in chronic leukemia: A report of three cases
26. Infections and serum IgG levels in patients with chronic lymphocytic leukemia
27. Infectious complications in chronic lymphocytic leukaemia
28. Infection and immunity in chronic lymphocytic leukemia
29. Infection and immunity in chronic lymphocytic leukemia
30. Infectious complications of neoplastic disease
31. Opportunistic infections in chronic lymphocytic leukemia
32. Cryptococcosis in a cancer hospital: Clinical and pathological correlates in forty-six patients
33. Histoplasmosis in immunosuppressed patients
34. Cryptococcal prostatitis in a patient with chronic lymphocytic leukemia
35. Infections in chronic lymphocytic leukemia; a reappraisal
36. Infectious and immunosuppressive complications of PA therapy
37. Complications in the treatment of CLL with purine analogues
38. Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas
39. The infectious complications of chronic lymphocytic leukemia
40. A meta-analysis of the relative efficacy and toxicity of Pnuemocystis carinii: Prophylactic regimens
41. Prophylactic strategies to meet infectious complications in fludarabine-treated CLL
42. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies
43. Immunophenotypic assessment of response in CLL after fludarabine
44. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia
45. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study
46. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia
47. Phase II study of subcutaneous Alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL)
48. Frequency of CMV pneumonia following alemtuzumab treatment in lymphoid malignancies: Review of 1538 patients
49. Infections in patients with chronic lymphocytic leukemia treated with fludarabine
50. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: A role for Pneumocystis carinii pneumonia prophylaxis